专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090099041A1 METHODS FOR MAKING NUCLEOTIDE PROBES FOR SEQUENCING AND SYNTHESIS 有权
标题翻译：制备用于测序和合成的核酸探针的方法
公开(公告)号：US20090099041A1
公开(公告)日：2009-04-16
申请号：US12187460
申请日：2008-08-07
申请人： George M. CHURCH , Kun Zhang , Joseph Chou
发明人： George M. CHURCH , Kun Zhang , Joseph Chou
IPC分类号： C40B50/06 , C12P19/34
CPC分类号： C12Q1/6813 , C12Q1/6837 , C12Q2535/113 , C12Q2537/143 , C12Q2565/543
摘要： Compositions and methods for making a plurality of probes for analyzing a plurality of nucleic acid samples are provided. Compositions and methods for analyzing a plurality of nucleic acid samples to obtain sequence information in each nucleic acid sample are also provided.
摘要翻译：提供了制备用于分析多个核酸样品的多个探针的组合物和方法。还提供了用于分析多个核酸样品以获得每个核酸样品中的序列信息的组合物和方法。

2. 发明授权

US08771950B2 Methods for making nucleotide probes for sequencing and synthesis 有权
标题翻译：用于测序和合成的核苷酸探针的方法
公开(公告)号：US08771950B2
公开(公告)日：2014-07-08
申请号：US12187460
申请日：2008-08-07
申请人： George M. Church , Kun Zhang , Joseph Chou
发明人： George M. Church , Kun Zhang , Joseph Chou
IPC分类号： C12Q1/68 , C07H21/04
CPC分类号： C12Q1/6813 , C12Q1/6837 , C12Q2535/113 , C12Q2537/143 , C12Q2565/543
摘要： Compositions and methods for making a plurality of probes for analyzing a plurality of nucleic acid samples are provided. Compositions and methods for analyzing a plurality of nucleic acid samples to obtain sequence information in each nucleic acid sample are also provided.
摘要翻译：提供了制备用于分析多个核酸样品的多个探针的组合物和方法。还提供了用于分析多个核酸样品以获得每个核酸样品中的序列信息的组合物和方法。

3. 发明申请

US20060141036A1 HMG-CoA reductase inhibitor extended release formulation 审中-公开
标题翻译： HMG-CoA还原酶抑制剂延长释放制剂
公开(公告)号：US20060141036A1
公开(公告)日：2006-06-29
申请号：US11355771
申请日：2006-02-16
申请人： Chih-Ming Chen , Joseph Chou , David Wong
发明人： Chih-Ming Chen , Joseph Chou , David Wong
IPC分类号： A61K9/22
CPC分类号： A61K9/0004 , A61K9/2018 , A61K9/2031 , A61K9/2886 , A61K31/22 , A61K31/366
摘要： Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed.
摘要翻译：用于降低人体血清胆固醇水平的控释口服固体剂型包括包含羟基取代萘的烷基酯（例如洛伐他汀）和控释载体的药物，使得该剂型提供了最大血浆浓度的平均时间在每天一次的基础上向人类患者口服给药后约10至约32小时发生的药物（T max max）。剂型提供治疗有效的降低血清胆固醇水平。还公开了降低人体血清胆固醇水平的方法。

4. 发明授权

US06855336B2 Omeprazole formulation 失效
标题翻译：奥美拉唑制剂
公开(公告)号：US06855336B2
公开(公告)日：2005-02-15
申请号：US10712505
申请日：2003-11-13
申请人： Chih-Ming Chen , Joseph Chou , Unchalee Kositprapa
发明人： Chih-Ming Chen , Joseph Chou , Unchalee Kositprapa
IPC分类号： A61K9/16 , A61K9/20 , A61K9/28 , A61K9/50 , A61K9/52 , A61K9/54 , A61K9/56 , A61K31/4439 , A61K9/14
CPC分类号： A61K9/2846 , A61K9/1617 , A61K9/1635 , A61K9/1652 , A61K9/2013 , A61K9/2077 , A61K9/2081 , A61K9/284 , A61K9/2866 , A61K9/2886 , A61K9/5078 , A61K31/4439
摘要： A stable pharmaceutical composition of omeprazole for oral administration which consists essentially of: (a) a core of Omeprazole or a pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of lysing and arginine; and (b) a single layer of coating on said core which comprises a layer of an enteric coating agent which is applied from an organic solvent based system.
摘要翻译：用于口服给药的奥美拉唑的稳定药物组合物，其基本上由以下组成：（a）奥美拉唑的核心或药学上相当的盐，填充剂和选自裂解和精氨酸的碱性物质; 和（b）在所述芯上的单层涂层，其包含从基于有机溶剂的体系施加的肠溶衣层。

5. 发明授权

US6106862A Once daily analgesic tablet 失效
标题翻译：每日一次止痛片
公开(公告)号：US6106862A
公开(公告)日：2000-08-22
申请号：US132796
申请日：1998-08-13
申请人： Chih-Ming Chen , Joseph Chou , David Wong
发明人： Chih-Ming Chen , Joseph Chou , David Wong
IPC分类号： A61K9/00 , A61K9/20 , A61K9/22 , A61K9/28 , A61K31/64 , A61K9/30
CPC分类号： A61K9/2886 , A61K31/64 , A61K9/0004 , A61K9/2054 , A61K9/282 , A61K9/2866 , A61K9/2013
摘要： An analgesic controlled release dosage form containing: (a) 40-80 weight percent of an analgesic; (b) 10-30 weight percent of a pharmaceutically acceptable filler; and (c) 10-30 weight percent of a carrier base wherein the carrier base is formed from a high molecular weight hydroxypropyl methylcellulose, a water soluble binder and optionally a water insoluble binder.
摘要翻译：镇痛控释剂型，其含有：（a）40-80重量％的止痛剂; （b）10-30重量％的药学上可接受的填料; 和（c）10-30重量％的载体碱，其中载体碱由高分子量羟丙基甲基纤维素，水溶性粘合剂和任选的水不溶性粘合剂形成。

6. 发明申请

US20110195119A1 CONTROLLED RELEASE METFORMIN FORMULATIONS 有权
标题翻译：控制释放金属配方
公开(公告)号：US20110195119A1
公开(公告)日：2011-08-11
申请号：US13052154
申请日：2011-03-21
申请人： Xiu Xiu Cheng , Chih-Ming Chen , Steve Jan , Joseph Chou
发明人： Xiu Xiu Cheng , Chih-Ming Chen , Steve Jan , Joseph Chou
IPC分类号： A61K9/22 , A61K31/155 , A61K9/30 , A61P3/10
CPC分类号： A61K9/2866 , A61K9/0004 , A61K9/2072 , A61K9/282 , A61K9/2886 , A61K31/155
摘要： Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.
摘要翻译：公开了包含抗高血糖药物或其药学上可接受的盐的缓释药物制剂。制剂在给药后24小时内向人类患者提供抗高血糖药物的治疗血浆水平。

7. 发明申请

US20070013681A1 Ambidextrous Multi-function Finger Adaptor 审中-公开
标题翻译：双面多功能手指适配器
公开(公告)号：US20070013681A1
公开(公告)日：2007-01-18
申请号：US11160838
申请日：2005-07-12
申请人： Joseph Chou
发明人： Joseph Chou
IPC分类号： G09G5/00
CPC分类号： G06F3/03543 , G06F2203/0332
摘要： An ambidextrous multi-function finger adaptor is proposed to facilitate the operation of various electronic equipments by the finger. The finger adaptor includes a removable wearing device for fixably enclosing a portion of the finger covering at least the finger pad. A first stylus tip is affixed to and projected from the removable wearing device at a first stylus location on the finger pad but offset from center of the finger pad toward a first edge of the finger. A second stylus tip is affixed to and projected from the removable wearing device at a second stylus location on the finger pad but offset from center of the finger pad toward a second edge of the finger. A third stylus tip is affixed to and projected from the removable wearing device at a third stylus location on the finger pad near a sensible center of feeling for writing.
摘要翻译：提出了一种双向多功能手指适配器，以便于手指对各种电子设备的操作。手指适配器包括可拆卸的佩戴装置，用于可固定地包围至少手指垫的手指的一部分。第一触笔尖端固定到可移除的佩戴装置上并且在指垫上的第一触针位置处突出，但是从指垫的中心朝向手指的第一边缘偏移。第二个触控笔头固定在可移除的佩戴装置上并在手指垫上的第二个触控笔位置突出，但是从指垫的中心偏移到手指的第二边缘。第三个触控笔头固定在可移动的佩戴装置上并在手指垫上的第三个触笔笔记位置处突出，靠近一个明智的写作感觉中心。

8. 发明申请

US20060141035A1 HMG-COA reductase inhibitor extended release formulation 有权
标题翻译： HMG-COA还原酶抑制剂延长释放制剂
公开(公告)号：US20060141035A1
公开(公告)日：2006-06-29
申请号：US11355335
申请日：2006-02-16
申请人： Chih-Ming Chen , Joseph Chou , David Wong
发明人： Chih-Ming Chen , Joseph Chou , David Wong
IPC分类号： A61K9/22
CPC分类号： A61K9/0004 , A61K9/2018 , A61K9/2031 , A61K9/2886 , A61K31/22 , A61K31/366
摘要： Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed.
摘要翻译：用于降低人体血清胆固醇水平的控释口服固体剂型包括包含羟基取代萘的烷基酯（例如洛伐他汀）和控释载体的药物，使得该剂型提供了最大血浆浓度的平均时间在每天一次的基础上向人类患者口服给药后约10至约32小时发生的药物（T max max）。剂型提供治疗有效的降低血清胆固醇水平。还公开了降低人体血清胆固醇水平的方法。

9. 发明申请

US20060008523A1 Controlled release metformin compositions 审中-公开
公开(公告)号：US20060008523A1
公开(公告)日：2006-01-12
申请号：US11224784
申请日：2005-09-13
申请人： Chih-Ming Chen , Xiu-Xiu Cheng , Steve Jan , Joseph Chou
发明人： Chih-Ming Chen , Xiu-Xiu Cheng , Steve Jan , Joseph Chou
IPC分类号： A61K9/22
CPC分类号： A61K31/155 , A61K9/0004 , A61K9/2027
摘要： A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.

10. 发明授权

US06790459B1 Methods for treating diabetes via administration of controlled release metformin 有权
标题翻译：通过施用控释二甲双胍治疗糖尿病的方法
公开(公告)号：US06790459B1
公开(公告)日：2004-09-14
申请号：US09705625
申请日：2000-11-03
申请人： Xiu Xiu Cheng , Chih-Ming Chen , Steve Jan , Joseph Chou
发明人： Xiu Xiu Cheng , Chih-Ming Chen , Steve Jan , Joseph Chou
IPC分类号： A61K914
CPC分类号： A61K9/0004 , A61K9/2866 , A61K31/155
摘要： A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.
摘要翻译：一种通过每天一次施用含有优选双胍类药物如二甲双胍的控释口服固体剂型来治疗患有非胰岛素依赖性糖尿病（NIDDM）的患者的方法。该剂型提供了在每天一次给予人类患者的口服给药后5.5至7.5小时时药物的最大血药浓度（Tmax）的平均时间。优选地，在晚餐时间向给喂状态的患者施用药物剂量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式